Effect of Aged Garlic Extract on Atherosclerosis (Garlic4)

This study is ongoing, but not recruiting participants.
Wakunaga Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Los Angeles Biomedical Research Institute
ClinicalTrials.gov Identifier:
First received: February 14, 2012
Last updated: September 22, 2014
Last verified: September 2014

February 14, 2012
September 22, 2014
May 2012
December 2014   (final data collection date for primary outcome measure)
improvement of vascular function [ Time Frame: 1 year ] [ Designated as safety issue: No ]
evaluating vascular function of the coronaries as based upon CT angiography
Same as current
Complete list of historical versions of study NCT01534910 on ClinicalTrials.gov Archive Site
  • Coronary calcium [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • CT angiography plaque [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Serum Biomarkers [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    cholesterol, inflammatory markers, oxidative biomarkers.
  • Carotid IMT [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    intima-media thickness
Same as current
Not Provided
Not Provided
Effect of Aged Garlic Extract on Atherosclerosis
Effect of Aged Garlic Extract on Atherosclerosis

The investigators will be assessing the effect of Aged Garlic Extract on the coronary arteries. The investigators will enroll patients in a double blind study, where half the patients will receive placebo, and have the patients undergo a series of tests of plaque (CT scan of the heart, carotid ultrasound) and follow the patients on the drug or placebo and then repeat the tests and blood work at the end of one year. The investigators will assess if being on aged garlic extract adds any benefit to plaque in the coronary or neck arteries. The investigators will also assess the effect of aged garlic extract on markers of inflammation. Patients will receive free drug, free testing and be compensated, and learn more about their heart and neck arteries. if successful, more patients can use this drug to benefit their health. The harms include the radiation from the CT scan and the medication, which has mild side effects.

Not Provided
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Metabolic Syndrome
  • Drug: aged garlic extract
    2400 mg a day
  • Drug: placebo
  • Placebo Comparator: Sugar pill
    Intervention: Drug: placebo
  • Active Comparator: Aged Garlic Extract
    2400 mg of aged garlic extract
    Intervention: Drug: aged garlic extract
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Age 40-65 years
  • Framingham risk score 6-20%, and at least 2 components of the metabolic syndrome as defined by ATP III Clinical Identification of the Metabolic Syndrome (including impaired fasting glucose > 110 mg/dl, treated hypertension or SBP > 130 or DBP > 85 mm Hg, plasma triglycerides > 150 mg/dl, HDL cholesterol < 35 mg/dl for men or < 40 mg/dl for women, abdominal obesity as defined as waist > 40 in for men, > 35 in for women)
  • Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
  • Subjects should be stable on their concomitant medications for at least 26 weeks prior to randomization
  • Calcium Score > 20 at baseline
  • Subjects who agree to refrain from other anti-glycemic agent Exclusion Criteria
  • A contraindication to AGE including: known hypersensitivity to drug.
  • Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
  • Weight in excess of 300 pounds
  • Bleeding disorder
  • History of known coronary artery disease, myocardial infarction, stroke or life-threatening arrhythmia within the prior six months
  • NYHA Class II- IV heart failure
  • History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy
  • Serum creatinine > 1.4 mg/dl
  • Diabetes Mellitus
  • Triglycerides > 400 at visit 1
  • Drug or alcohol abuse, or current intake of more than 14 standard drinks per week
  • Concurrent enrollment in another placebo-controlled trial
  • Partial ileal bypass or known gastrointestinal disease limiting drug absorption
  • Current diabetes or intake of anti-diabetic or other prohibited drug
  • Current tobacco use
  • Current use of anticoagulants (except for anti-platelet agents)
  • Renal failure
  • History of hypertensive encephalopathy or cerebrovascular accident
  • Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI
40 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
United States
Los Angeles Biomedical Research Institute
Los Angeles Biomedical Research Institute
Wakunaga Pharmaceutical Co., Ltd.
Principal Investigator: Matthew Budoff, MD Los Angeles Biomedical Research Institute
Los Angeles Biomedical Research Institute
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP